Novartis AG (NYSE:NVS) moved down -0.13% and closed its last trading session at $71.26. This Medical Sector stock currently has the Market Capitalization of 192.27 Billion. The Average Volume for the stock is measured as 1.9 Million. The Stock has a 52-Week High of $90.97 and 52-Week Low of $69.9 following the dates, it touched its 52-Week High on Nov 5, 2015 and 52-Week Low on Apr 1, 2016. Currently, the Return on Assets value for the trailing twelve months is 0% with the Return on Equity and Return on Investment of 0% and 7.8% respectively. This firm currently has YTD (year to date) performance of -13.95 Percent which is not good. The Short Ratio for the stock is 1.8.
Novartis AG (NYSE:NVS) Price to Earnings (P/E) ratio is 25.77. EPS or Earning per Share stands at $2.77. The TTM operating margin is 0 percent.
Novartis AG (NYSE:NVS) is due to report its Earnings on Tue 25 Oct (8 days ago). The estimated EPS for the current quarter is said to be $1.18. Following Earnings result, share price were UP 4 times out of last 7 Qtrs. The stock has reduced about -5.4% since it reported its last earnings. The Closing price of Novartis AG (NYSE:NVS) at Last Earnings was $75.45 as compared to the previous closing price of $71.35. The Predicted Move on the 7th day after Novartis AG (NYSE:NVS) will release its earnings at about 2%.
By Looking at Earnings History, Out of 12 Quarters when the Earnings were reported, Novartis AG (NYSE:NVS) beats earnings by 41%%, The Stock Missed Earnings 6 times and has met earnings 1 times.
We will discuss the past 3 Quarters Earnings below:
Novartis AG (NYSE:NVS) reported its previous quarter on 10/25/2016 where it reported the Actual Earnings of $1.23. The Closing price before the company posted its earnings was $75.45. The Stock declined on the very next day of earnings and maintained its stock price at $72.63 by showing a % change of -3.74 percent from its previous closing price. The Next Day Volume after Earnings was reported as 6.13 Million. On the 7th day After Earnings Report, the stock hit its share price as $71.02 by showing -5.87% decrease from the Stock price Before Earnings were reported.
On 07/19/2016, the stock reported the EPS of $1.23 where Analysts were projecting the EPS to be $1.18 showing a difference of $0.05. Thus Surprise Factor was there with 4.2 percent. Before Earnings Announcement on 07/19/2016, the firm had its stock price of $82.04. And immediately on the next day after earnings announcement, the stock declined -0.62% and closed its trading session at $81.53. On 7th Day after earnings release, Novartis AG (NYSE:NVS) surged to 1.73% from $82.04 to $83.46.
On 04/21/2016, Analysts were suspecting EPS of $1.18/share where Novartis AG (NYSE:NVS) reported its Actual EPS of $1.16. Thus showing a Surprise of -1.7 percent. The Closing Price of the stock before earnings was $76.59 while on the Next day the stock closed its trading session at $76.28 with a percentage change of -0.4% from the price of 76.59 before Earnings. The Stock Closing Price on the 7th day of earnings was $76.98.
Novartis AG researches, develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Pharmaceuticals, Alcon, and Sandoz. The Pharmaceuticals segment offers patented prescription medicines for oncology, neuroscience, retina, immunology and dermatology, respiratory, cardio-metabolic, established medicines, and cell and gene therapies. The Alcon segment provides eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye, and over-the-counter medicines for the eye; and contact lenses and lens care products. The Sandoz segment offers generic prescription medicines that include active ingredients and finished dosage forms of pharmaceuticals for dermatology, respiratory and ophthalmic, cardiovascular, metabolism, central nervous system, pain, gastrointestinal, and hormonal therapies; active pharmaceutical ingredients and intermediates primarily antibiotics; protein or other biotechnology-based products; and cytotoxic products for the hospital markets, as well as biotechnology manufacturing services to other companies. The company has collaboration and licensing agreements with Intellia Therapeutics for the discovery and development of new medicines using CRISPR genome editing technology; and with Caribou Biosciences for the development of drug discovery tools. It also has a strategic collaboration with Cerulean Pharma to develop nanoparticle-drug conjugates for various cancer tumor targets; and a collaboration agreement with Perlara PBC to identify definitive therapeutics for lysosomal storage disorders. Novartis AG was founded in 1895 and is headquartered in Basel, Switzerland.